TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04049201

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: elective surgery
Description: investigators will compare the effect of interactive tablet on preoperative anxiety in children to the effect ofMidazolam in elective surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: elective surgery
Description: investigators will compare the effect of interactive tablet on preoperative anxiety in children to the effect ofMidazolam in elective surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: Oral Midazolam

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Interactive Tablet
Description: interactive Tablet containing many cartoon's videos
Study: NCT03055585

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Wolbachia-infected Aedes aegypti mosquitoes
Description: Deployment of Wolbachia-infected Aedes aegypti mosquitoes

Intervention type: OTHER
Group type: OTHER
Intervention: standard practice dengue control
Description: standard practice dengue control activities conducted by dengue control program

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: standard practice dengue control
Description: standard practice dengue control activities conducted by dengue control program
Study: NCT00798395

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Org 50081
Description: 1.5 mg on day 1-7

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Org 50081
Description: 4.5 mg on Day 1-7

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once daily on Day 1-7

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: zopiclone
Description: Single dose of 7.5 mg
Study: NCT03038074

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pulse Oximeter with respiration rate sensor
Study: NCT02174198

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BioOss Collagen at the time of implant placement
Description: Experimental: placement of BioOss Collagen No intervention: no BioOss Collagen
Study: NCT03049982

Intervention type: DEVICE
Group type: OTHER
Intervention: Auto-titrating mandibular positioner test
Description: Participants will undergo a theragnostic test using the auto-titrating mandibular positioner to determine if they are eligible candidates to use oral appliance therapy for their obstructive sleep apnea. The device works by moving the lower jaw forward in response to respiratory events while the participant sleeps. All participants will undergo the same test.
Study: NCT01548443

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medifoam H dressing
Description: Cover medifoam H on the wound for a week.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Duoderm THIN dressing
Description: Cover Duoderm THIN on the wound for a week
Study: NCT01710293

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Communication of Patients Lost to Follow-up to Providers
Description: The investigators will query the VA's database weekly to identify possible lost to follow-up events for a random sample of about half of the providers at our study sites. The queries will use the trigger criteria developed in our previous work for colorectal cancer, lung cancer, hepatocellular carcinoma, breast cancer, and bladder cancer. The list of trigger positive patients will be transmitted to a facility-level recipient who will either disseminate the information to existing facility individual cancer care coordinators/trackers or will review the charts of the triggered patients in order to determine whether these patients have been truly lost to follow-up or not. If patients are found to be lost to follow-up, the Facility Recipient or cancer care coordinator/tracker will communicate the need for follow-up to the PACT or primary care provider, using secure emails, phone calls, or in person, depending on which method of communication they deem most appropriate and effective.
Study: NCT02377765

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Stimulation
Description: TPTNS through a TENS unit is a non-invasive technique, easily manageable by patients, which lacks some adverse side effects reported with the use of PTNS, such as bleeding and/or pain at the site of needle insertion. As the technique is self-administered, the associated costs might be substantially lower when compared to PTNS, which involves repeated Hospital appointments for maintenance therapy.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneus Stimulation
Description: PTNS aims to stimulate the sacral nerve plexus (origin to the parasympathetic innervations to the bladder) through the afferent fibres of the posterior tibial nerve, a mixed nerve containing L5-S3 fibres (Slovak, Chapple and Barker, 2014). This is achieved by a needle electrode inserted above the medial malleolus. Interestingly, this anatomical area is known as acupuncture point Spleen6 (Sp6).
Study: NCT02419547

Intervention type: DRUG
Group type: OTHER
Intervention: Versed
Description: Phase 1: Standard induction of controled sedation with intravenous agent then programed stimulation to induce ventricular tachycardia

Intervention type: DRUG
Group type: OTHER
Intervention: Fentanyl
Description: Phase 1: Standard induction of controled sedation with intravenous agent then programed stimulation to induce ventricular tachycardia

Intervention type: DRUG
Group type: OTHER
Intervention: Propofol
Description: Phase 2: Standard induction of GETA with intravenous agent then programed stimulation to induce ventricular tachycardia

Intervention type: DRUG
Group type: OTHER
Intervention: Sevoflurane
Description: Phase 3: Standard induction of GETA with inhalent agent then programed stimulation to induce ventricular tachycardia
Study: NCT03076359

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Traditional Healer Support Program
Description: Traditional Healers will provide the traditional healer support program assistance, as previously described, to all newly diagnosed patients.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: First-line ART will consist of two nucleoside reverse-transcriptase inhibitors (NRTIs) plus a non-nucleoside reverse-transcriptase inhibitor (NNRTI)- TDF + 3TC (or FTC) + EFV as a fixed-dose combination to be taken twice a day for the rest of the patient's life), clinic-based counseling, and community searches if lost to follow up.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: First-line ART will consist of two nucleoside reverse-transcriptase inhibitors (NRTIs) plus a non-nucleoside reverse-transcriptase inhibitor (NNRTI)- TDF + 3TC (or FTC) + EFV as a fixed-dose combination to be taken twice a day for the rest of the patient's life), clinic-based counseling, and community searches if lost to follow up.
Study: NCT00147979

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bridging by PTFE with bounded heparin
Description: Bridging by PTFE with bounded heparin

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bridging by PTFE without bounded heparin
Description: Bridging by PTFE without bounded heparin
Study: NCT02268396

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glycopyrronium and Formoterol Fumarate Metered-dose Inhaler
Description: GFF MDI administered as 2 inhalations BID
Study: NCT01109303

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TightRope System- Arthrex® / Dynamic Implant
Description: Patients are operated on using a dynamic implant, the TightRope System by Arthrex®. The ankle is immobilized in a plaster boot for 6 weeks.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Screw fixation - Synthes® / Static Implant
Description: Patients are operated on using a static implant, the rigid four-cortices 3,5 mm screw fixation by Synthes®. The ankle is immobilized in a plaster boot for 6 weeks.
Study: NCT02590133

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Human Endostatin Injection (Endostar)
Description: 15mg/m2/d, continuous intravenous infusion in 2ml/h for 30 days each cycle, 60 days as one cycle, 6 cycles in total

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluorouracil (5-Fu)
Description: 200mg/m2/d, continuous intravenous infusion in 2ml/h for 30 days each cycle, 60 days as one cycle, 6 cycles in total
Study: NCT01455090

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-650032

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-650032
Study: NCT00754507

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: colesevelam HCl tablets, and atorvastatin tablets
Description: colesevelam HCl tablets,6 tablets/day; atorvastatin tablets, 1 tablets/day for 6 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: colesevelam HCl placebo tablets and atorvastatin tablets
Description: colesevelam HCl placebo tablets, 6 tablets/day for 6 weeks atorvastatin tablets, 1 tablet/day for 6 weeks
Study: NCT02590133

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil (5-Fu)
Description: 200mg/m2/d, continuous intravenous infusion in 2ml/h for 30 days each cycle, 60 days as one cycle, 6 cycles in total
Study: NCT00675285

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: one tablet 5 mg once/day for 4 weeks
Study: NCT02590133

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nedaplatin
Description: 80mg/m2/d, intravenous drip on d1 and d28 each cycle, 60 days as one cycle, 6 cycles in total

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nedaplatin
Description: 80mg/m2/d, intravenous drip on d1 and d28 each cycle, 60 days as one cycle, 6 cycles in total
Study: NCT01808443

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cryotherapy
Description: up to a maximum of four treatments every 21-28 days

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laser
Description: up to a maximum of four treatments every 21-28 days
Study: NCT03138083

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OMO-1
Description: OMO-1 is a small molecule inhibitor of the enzymatic activity of the MET receptor tyrosine kinase

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OMO-1
Description: OMO-1 is a small molecule inhibitor of the enzymatic activity of the MET receptor tyrosine kinase
Study: NCT02236585

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Patient-controlled epidural analgesia
Description: Patients will receive with patient controlled background infusion of 0.125% bupivacaine plus 2 μg/ml fentanyl that will be set between 4-6 ml/hour (to maintain visual analog scale (VAS) of ≥ 50 mm), intermittent bolus of 10 ml on demand by the women with lockout interval of 20 min with a four-hour maximum dose of 100 mL, irrespective of their age. The epidural infusions will be maintained for the first 24 postoperative hours

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Continuous epidural analgesia
Description: Patients will receive continuous epidural infusion of 0.125% bupivacaine plus 2 μg/ml fentanyl at rate of 6-15 ml/hour (to maintain visual analog scale (VAS) of ≥ 50 mm).
Study: NCT01311596

Intervention type: OTHER
Intervention: Icons
Description: Clinic- patients first shown picture icons of the steps of taking vital signs Lab - patients first shown picture icons of the steps of a blood draw procedure
Study: NCT01947738

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VBY-891
Description: Cathepsin S inhibitor
Study: NCT03138083

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OMO-1
Description: OMO-1 is a small molecule inhibitor of the enzymatic activity of the MET receptor tyrosine kinase

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OMO-1
Description: OMO-1 is a small molecule inhibitor of the enzymatic activity of the MET receptor tyrosine kinase

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OMO-1
Description: OMO-1 is a small molecule inhibitor of the enzymatic activity of the MET receptor tyrosine kinase
Study: NCT01947738

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03138083

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OMO-1
Description: OMO-1 is a small molecule inhibitor of the enzymatic activity of the MET receptor tyrosine kinase
Study: NCT04122053

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention group with genotype information
Description: Results of genotyping will be translated into personalised dietary recommendations. Subjects will be informed about their genotypes from the beginning of the study. The importance of personalised recommendations will be explained.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control group without genotype information
Description: Subjects will receive personalised dietary recommendations, but at the beginning they will not be informed about their genotypes and the meaning of personalisation. Information about their genotype will be given to the participants at the and of study.
Study: NCT03739385

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: The training interventions of all three groups (intergenerational group, peer group seniors, peer group children) will occur under professional supervision twice a week lasting over a 25-week period with training sessions lasting 45 minutes each. Control groups (control group seniors, control group children) receive no intervention.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Intervention
Description: The training interventions of all three groups (intergenerational group, peer group seniors, peer group children) will occur under professional supervision twice a week lasting over a 25-week period with training sessions lasting 45 minutes each. Control groups (control group seniors, control group children) receive no intervention.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Intervention
Description: The training interventions of all three groups (intergenerational group, peer group seniors, peer group children) will occur under professional supervision twice a week lasting over a 25-week period with training sessions lasting 45 minutes each. Control groups (control group seniors, control group children) receive no intervention.
Study: NCT02372331

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ERAS perioperative management
Description: * Preop Counseling~* Preop biliary drainage (X) when Serum Total bilirubin \< 14.62mg/dl and cholangitis (-)~* Preop enteral nutrition~* Oral bowel preparation (mechanical bowel preparation ) (X)~* Preop fasting \< 6 hours~* Prevention of postoperative nausea and vomiting (PONV) (O)~* Nasogastric intubation (X)~* Near-zero fluid balance~* Somatostatin analogues (X)~* Postop routine artificial nutrition (X), soft diet at POD #2~* Audit~* Other items are same as conventional
Study: NCT02187211

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for Minocycline)
Study: NCT03708380

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary intervention
Description: Over a 60-day period, participants will receive healthy lunches that provide a hand-delivered healthy alterative to their current diets.
Study: NCT04612114

Intervention type: DIAGNOSTIC_TEST
Intervention: Belun Ring
Description: Simultaneous recording of Belun Ring data (pulse oximeter, pulse rate and actigraphy) and standard of care PSG will be performed for one night.
Study: NCT01540435

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab at a dose of 5 mg/kg iv over 30 to 90 min (day 1) + FOLFOXIRI in a biweekly schedule, 6 cycles preoperatively, 6 cycles postoperatively
Study: NCT01421043

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: triazolam liquid oral drops
Description: 0.25 mg single dose oral drops

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: triazolam tablets
Description: 0.25 mg single oral dose
Study: NCT01547104

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linagliptin
Description: Linagliptin dosed 5 mg as add on therapy to an existing metformin therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glimepiride
Description: Glimepiride 1-4mg (individually dosed) as add on therapy to an existing metformin therapy
Study: NCT01333943

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Study Group: Experimental
Description: The study group will receive the saphenous nerve block, at the level of the adductor canal. The block will be under ultrasound guidance. The local anesthetic will be 15 ml of 0.5% bupivicaine. The study group will also receive a combined spinal epidural, with 2.5 ml of 0.5% bupivacaine as the spinal agent. Additional drugs include anti-emetics, specifically Ondansetron (4 mg).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: The control group will receive the femoral nerve block. The block will be under ultrasound guidance. The local anesthetic will be 30 ml of 0.25% bupivicaine. The control group will also receive a combined spinal epidural, with 2.5 ml of 0.5% bupivacaine as the spinal agent. Additional drugs include anti-emetics, specifically Ondansetron (4 mg).
Study: NCT06163716

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multidomain intervention (MD-Int) group
Description: The MD-Int program included: 1) individual follow-up visits every three months for cardiovascular risk factor monitoring and nutritional counselling with primary health care providers; 2) two nutritional workshops led by a nutritionist; 3) 20 hours of cognitive stimulation delivered through group sessions and 4) 40 hours of individual cognitive training exercises. Participants in the MD-Int group received recommendations to practice 2 to 6 hours of physical exercise per week and get involved in sports activities. Social stimulation was promoted through group activities.
Study: NCT03701425

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Mediterranean diet and exercise plan
Description: Mediterranean diet:~Diet: according to the definition, with the following distribution of macro nutrients:~Protein contribution 0.8-1.2 Carbon Hydrates 45-50% Lipids 30%

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Mediterranean diet and exercise plan
Description: Mediterranean diet:~Diet: according to the definition, with the following distribution of macro nutrients:~Protein contribution 0.8-1.2 Carbon Hydrates 45-50% Lipids 30%

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Mediterranean diet and exercise plan
Description: Mediterranean diet:~Diet: according to the definition, with the following distribution of macro nutrients:~Protein contribution 0.8-1.2 Carbon Hydrates 45-50% Lipids 30%

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Mediterranean diet and exercise plan
Description: Mediterranean diet:~Diet: according to the definition, with the following distribution of macro nutrients:~Protein contribution 0.8-1.2 Carbon Hydrates 45-50% Lipids 30%
Study: NCT01561690

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARRY-502, CRTh2 antagonist; oral
Description: multiple dose, single schedule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo; oral
Description: matching placebo
Study: NCT03483077

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 730460
Description: tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 730460
Description: tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 730460
Description: tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 730460
Description: tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 730460
Description: tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 730460
Description: tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: tablets
Study: NCT04292847

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Referrals Recommendations
Description: All participants will complete the geriatric assessment and receive Referral recommendations based on the assessment.
Study: NCT00505245

Intervention type: OTHER
Intervention: Interview
Description: Complete interview

Intervention type: OTHER
Intervention: Quality-of-Life Assessment
Description: Complete quality of life assessment

Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Complete questionnaires
Study: NCT00563992

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lithium
Description: Participants may also be required to take the antidepressant paroxetine and/or the medication olanzapine for a portion of the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valproic acid
Description: Participants may also be required to take the antidepressant paroxetine and/or the medication olanzapine for a portion of the study.
Study: NCT03904628

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TG02 capsules oral administration, BIW in every 28d
Description: TG02 capsules150mg oral administration, BIW in every 28d

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TG02 capsules oral administration, BIW in every 28d
Description: TG02 capsules 200mg oral administration, BIW in every 28d

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TG02 capsules oral administration, BIW in every 28d
Description: TG02 capsules 250mg oral administration, BIW in every 28d
Study: NCT01599416

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: U-relax
Description: Oral U-relax Day 1-5: 2 capsuals before sleep Day 6-360: 1 capsual before sleep

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: U-relax
Description: Oral U-relax Day 1-5: 2 capsuals before sleep Day 6-360: 1 capsual before sleep
Study: NCT00773071

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SPECT/CT guided LM/SL
Description: Pre-operatively, SLNs will be detected by low-dose SPECT/CT (99mTc-cystein rhenium colloids, 1cc/1mCi). Intra-operatively, a blue-dye (Patent Blue, 2cc) and a gamma-probe guidance will be used to detect the SLN nodes. All blue-stained and/or hot lymph nodes with a radioactivity greater than 10% of the hottest node will be considered as SLNs. Serial sections of SLNs will be analyzed by H-E staining. In cases of negative H-E, the SLNs will be further analyzed by immunochemistry (CKAE1/CKAE3, and high molecular weight Cytokeratin 34BE12). Non-SLNs will be analyzed as usual in routine by H-E.